Andrew Knyazev is an American mathematician. He graduated from the Faculty of Computational Mathematics and Cybernetics of Moscow State University under the supervision of Evgenii Georgievich D'yakonov (Russian: Евгений Георгиевич Дьяконов) in 1981 and obtained his PhD in Numerical Mathematics at the Russian Academy of Sciences under the supervision of Vyacheslav Ivanovich Lebedev (Russian: Вячеслав Иванович Лебедев) in 1985. He worked at the Kurchatov Institute between 1981–1983, and then to 1992 at the Marchuk Institute of Numerical Mathematics (Russian: ru:Институт вычислительной математики имени Г. И. Марчука РАН) of the Russian Academy of Sciences, headed by Gury Marchuk (Russian: Гурий Иванович Марчук). From 1993–1994, Knyazev held a visiting position at the Courant Institute of Mathematical Sciences of New York University, collaborating with Olof B. Widlund. From 1994 until retirement in 2014, he was a Professor of Mathematics at the University of Colorado Denver, supported by the National Science Foundation and United States Department of Energy grants. He was a recipient of the 2008 Excellence in Research Award, the 2000 college Teaching Excellence Award, and a finalist of the CU President's Faculty Excellence Award for Advancing Teaching and Learning through Technology in 1999. He was awarded the title of Professor Emeritus at the University of Colorado Denver and named the SIAM Fellow Class of 2016 and AMS Fellow Class of 2019. From 2012–2018, Knyazev worked at the Mitsubishi Electric Research Laboratories on algorithms for image and video processing, data sciences, optimal control, and material sciences, resulting in dozens of publications and 13 patent applications. Since 2018, he contributed to numerical techniques in quantum computing at Zapata Computing, real-time embedded anomaly detection in automotive data, and algorithms for silicon photonics-based hardware. Knyazev is mostly known for his work in numerical solution of large sparse eigenvalue problems, particularly preconditioning and the iterative method LOBPCG. Knyazev's implementation of LOBPCG is available in many open source software packages, e.g., BLOPEX, SciPy, and ABINIT. Knyazev collaborated with John Osborn on the theory of the Ritz method in the finite element method context and with Nikolai Sergeevich Bakhvalov (Russian: Николай Серге́евич Бахвалов) (Erdős number 3 via Leonid Kantorovich) on numerical solution of elliptic partial differential equations with large jumps in the main coefficients. Jointly with his Ph.D. students, Knyazev pioneered using majorization for bounds in the Rayleigh–Ritz method (see and references there) and contributed to the theory of angles between flats.
Semi-automation
Semi-automation is a process or procedure that is performed by the combined activities of man and machine with both human and machine steps typically orchestrated by a centralized computer controller. Within manufacturing, production processes may be fully manual, semi-automated, or fully automated. In this case, semi-automation may vary in its degree of manual and automated steps. Semi-automated manufacturing processes are typically orchestrated by a computer controller which sends messages to the worker at the time in which he/she should perform a step. The controller typically waits for feedback that the human performed step has been completed via either a human-machine interface or via electronic sensors distributed within the process. Controllers within semi-automated processes may either directly control machinery or send signals to machinery distributed within the process. Centralized computer controllers within semi-automated processes orchestrate processes by instructing the worker, providing electronic communication and control to process equipment, tools, or machines, as well as perform data management to record and ensure that the process meets established process criteria. Many manufacturers choose not to fully automate a process, and instead implement semi-automation due to the complexity of the task, or the number of products produced is too low to justify the investment in full automation. Other processes may not be fully automated because it may reduce the flexibility to easily adapt the processes to reflect production needs.
How to Choose an AI Humanizer
In search of the best AI humanizer? An AI humanizer is software that uses machine learning to help you get more done — it turns a rough idea into a polished result in seconds. When choosing one, weigh output quality, pricing, export formats, and how well it fits the tools you already use. Whether you are a beginner or a pro, the right AI humanizer slots into your workflow and pays for itself fast. We tested the leading options and ranked them by quality, value, and ease of use.
Sequential minimal optimization
Sequential minimal optimization (SMO) is an algorithm for solving the quadratic programming (QP) problem that arises during the training of support-vector machines (SVM). It was invented by John Platt in 1998 at Microsoft Research. SMO is widely used for training support vector machines and is implemented by the popular LIBSVM tool. The publication of the SMO algorithm in 1998 has generated a lot of excitement in the SVM community, as previously available methods for SVM training were much more complex and required expensive third-party QP solvers. == Optimization problem == Consider a binary classification problem with a dataset (x1, y1), ..., (xn, yn), where xi is an input vector and yi ∈ {-1, +1} is a binary label corresponding to it. A soft-margin support vector machine is trained by solving a quadratic programming problem, which is expressed in the dual form as follows: max α ∑ i = 1 n α i − 1 2 ∑ i = 1 n ∑ j = 1 n y i y j K ( x i , x j ) α i α j , {\displaystyle \max _{\alpha }\sum _{i=1}^{n}\alpha _{i}-{\frac {1}{2}}\sum _{i=1}^{n}\sum _{j=1}^{n}y_{i}y_{j}K(x_{i},x_{j})\alpha _{i}\alpha _{j},} subject to: 0 ≤ α i ≤ C , for i = 1 , 2 , … , n , {\displaystyle 0\leq \alpha _{i}\leq C,\quad {\mbox{ for }}i=1,2,\ldots ,n,} ∑ i = 1 n y i α i = 0 {\displaystyle \sum _{i=1}^{n}y_{i}\alpha _{i}=0} where C is an SVM hyperparameter and K(xi, xj) is the kernel function, both supplied by the user; and the variables α i {\displaystyle \alpha _{i}} are Lagrange multipliers. == Algorithm == SMO is an iterative algorithm for solving the optimization problem described above. SMO breaks this problem into a series of smallest possible sub-problems, which are then solved analytically. Because of the linear equality constraint involving the Lagrange multipliers α i {\displaystyle \alpha _{i}} , the smallest possible problem involves two such multipliers. Then, for any two multipliers α 1 {\displaystyle \alpha _{1}} and α 2 {\displaystyle \alpha _{2}} , the constraints are reduced to: 0 ≤ α 1 , α 2 ≤ C , {\displaystyle 0\leq \alpha _{1},\alpha _{2}\leq C,} y 1 α 1 + y 2 α 2 = k , {\displaystyle y_{1}\alpha _{1}+y_{2}\alpha _{2}=k,} and this reduced problem can be solved analytically: one needs to find a minimum of a one-dimensional quadratic function. k {\displaystyle k} is the negative of the sum over the rest of terms in the equality constraint, which is fixed in each iteration. The algorithm proceeds as follows: Find a Lagrange multiplier α 1 {\displaystyle \alpha _{1}} that violates the Karush–Kuhn–Tucker (KKT) conditions for the optimization problem. Pick a second multiplier α 2 {\displaystyle \alpha _{2}} and optimize the pair ( α 1 , α 2 ) {\displaystyle (\alpha _{1},\alpha _{2})} . Repeat steps 1 and 2 until convergence. When all the Lagrange multipliers satisfy the KKT conditions (within a user-defined tolerance), the problem has been solved. Although this algorithm is guaranteed to converge, heuristics are used to choose the pair of multipliers so as to accelerate the rate of convergence. This is critical for large data sets since there are n ( n − 1 ) / 2 {\displaystyle n(n-1)/2} possible choices for α i {\displaystyle \alpha _{i}} and α j {\displaystyle \alpha _{j}} . == Related work == The first approach to splitting large SVM learning problems into a series of smaller optimization tasks was proposed by Bernhard Boser, Isabelle Guyon, and Vladimir Vapnik. It is known as the "chunking algorithm". The algorithm starts with a random subset of the data, solves this problem, and iteratively adds examples which violate the optimality conditions. One disadvantage of this algorithm is that it is necessary to solve QP-problems scaling with the number of SVs. On real world sparse data sets, SMO can be more than 1000 times faster than the chunking algorithm. In 1997, E. Osuna, R. Freund, and F. Girosi proved a theorem which suggests a whole new set of QP algorithms for SVMs. By the virtue of this theorem a large QP problem can be broken down into a series of smaller QP sub-problems. A sequence of QP sub-problems that always add at least one violator of the Karush–Kuhn–Tucker (KKT) conditions is guaranteed to converge. The chunking algorithm obeys the conditions of the theorem, and hence will converge. The SMO algorithm can be considered a special case of the Osuna algorithm, where the size of the optimization is two and both Lagrange multipliers are replaced at every step with new multipliers that are chosen via good heuristics. The SMO algorithm is closely related to a family of optimization algorithms called Bregman methods or row-action methods. These methods solve convex programming problems with linear constraints. They are iterative methods where each step projects the current primal point onto each constraint.
Kunihiko Fukushima
Kunihiko Fukushima (Japanese: 福島 邦彦, born 16 March 1936) is a Japanese computer scientist, most noted for his work on artificial neural networks and deep learning. He is currently working part-time as a senior research scientist at the Fuzzy Logic Systems Institute in Fukuoka, Japan. == Notable scientific achievements == In 1980, Fukushima published the neocognitron, the original deep convolutional neural network (CNN) architecture. Fukushima proposed several supervised and unsupervised learning algorithms to train the parameters of a deep neocognitron such that it could learn internal representations of incoming data. Today, however, the CNN architecture is usually trained through backpropagation. This approach is now heavily used in computer vision. In 1969 Fukushima introduced the ReLU (Rectifier Linear Unit) activation function in the context of visual feature extraction in hierarchical neural networks, which he called "analog threshold element". (Though the ReLU was first used by Alston Householder in 1941 as a mathematical abstraction of biological neural networks.) As of 2017 it is the most popular activation function for deep neural networks. == Education and career == In 1958, Fukushima received his Bachelor of Engineering in electronics from Kyoto University. He became a senior research scientist at the NHK Science & Technology Research Laboratories. In 1989, he joined the faculty of Osaka University. In 1999, he joined the faculty of the University of Electro-Communications. In 2001, he joined the faculty of Tokyo University of Technology. From 2006 to 2010, he was a visiting professor at Kansai University. Fukushima acted as founding president of the Japanese Neural Network Society (JNNS). He also was a founding member on the board of governors of the International Neural Network Society (INNS), and president of the Asia-Pacific Neural Network Assembly (APNNA). He was one of the board of governors of the International Neural Network Society (INNS) in 1989-1990 and 1993-2005. == Awards == In 2020, Fukushima received the Bower Award and Prize for Achievement in Science. In 2022, Fukushima became a laureate of the Asian Scientist 100 by the Asian Scientist. He also received the IEICE Achievement Award and Excellent Paper Awards, the IEEE Neural Networks Pioneer Award, the APNNA Outstanding Achievement Award, the JNNS Excellent Paper Award and the INNS Helmholtz Award.
GoodRx
GoodRx Holdings, Inc. is an American healthcare company that operates a telemedicine platform and free-to-use website and mobile app that track prescription drug prices in the United States and provide drug coupons for discounts on medications. GoodRx compares prescription drug prices at more than 75,000 pharmacies in the United States. The platform allows users to consult a doctor online and obtain a prescription for certain types of medications. == History == === Financial performance === GoodRx was founded in Santa Monica, California in 2011. GoodRx experienced substantial growth in net income in 2017 ($9 million), 2018 ($44 million), and 2019 ($66 million), but recorded a loss of $293.6 million in 2020 due to IPO-related expenses. In September 2020, GoodRx went public on the Nasdaq under the ticker symbol GDRX. The company priced its initial public offering at $33 per share, above the expected range of $24 to $28, raising more than $1.1 billion at an initial valuation of approximately $12.7 billion. In the first half of 2020, the company reported revenues of $257 million and net income of $55 million. GoodRx generated $745.4 million in revenue for the full year 2021, a 35.36% increase over 2020. During the first half of 2021, the company’s share price declined by 10.7%. The decline was attributed to increased competition in online pharmacy services and slower user growth. GoodRx reported full-year revenue of $766.6 million, with adjusted EBITDA reaching $213.5 million, exceeding guidance in the fourth quarter. GoodRx reported that 41% of prescriptions filled using its coupons were newly adherent, meaning they would not have been filled without the service. GoodRx reported a full-year 2023 revenue of $750.3 million, a decrease of 2.1% from 2022. However, its fourth-quarter revenue increased by 7% year-over-year. GoodRx achieved an Adjusted EBITDA of $217.4 million for the year and an Adjusted EBITDA Margin of 28.6%. In 2024, GoodRx achieved 6% revenue growth with $792.3 million for the full year and turned a net loss into a positive net income of $16.4 million. The company also demonstrated strong operational efficiency, with a 32.8% increase in full-year Adjusted EBITDA. In Q2 2025, GoodRx reported revenue of $203.1 million, a 1.2% increase from the previous year, and a net income of $12.8 million, a significant 92% jump, which resulted in a 6.3% net income margin. However, prescription transaction revenue declined by 3% due to a decrease in monthly active consumers, but this was offset by strong 32% growth in its Pharma Manufacturer Solutions business. GoodRx also saw a 7% decrease in subscription revenue. === Mergers and acquisitions === In 2019, GoodRx acquired HeyDoctor, a telemedicine company, to integrate virtual healthcare services into the platform. In 2021, a health video content producer, HealthiNation was acquired by GoodRx, which helped provide consumers with health information and offered pharmaceutical manufacturers new ways to reach relevant audiences. In April 2022, GoodRx acquired VitaCare Prescription Services from TherapeuticsMD to strengthen its pharma manufacturer solutions business. === Partnerships === In 2017, the company announced partnerships with major pharmaceutical companies to negotiate lower prescription drug costs. GoodRx has deep relationships with major pharmacy chains, including Walgreens, Walmart, CVS Caremark, and Publix, to allow customers to use GoodRx discounts and Gold benefits. GoodRx began its partnership with CVS Caremark in July 2023 to automatically apply coupons to insured CVS customers purchasing generic prescriptions at certain locations. In April 2024, GoodRx added Publix into its network, allowing GoodRx Gold members to use their cards at Publix Pharmacies. GoodRx partners with Pharmacy Benefit Management like Caremark, Express Scripts, and MedImpact to apply their savings directly to eligible insurance plans and members. GoodRx partners with companies like Affirm, Benefitfocus, and DoorDash to integrate their services that offer members discounts and financial flexibility for prescriptions. GoodRx also partners with organizations like the American Academy of Family Physicians Foundation to support broader access to care. In October 2022, GoodRx launched Provider Mode, which allows healthcare providers to use the app to compare costs of drugs for patients based on different payment methods and drug alternatives. In 2025, GoodRx partnered with Novo Nordisk to offer discounted cash-pay access to semaglutide products like Ozempic and Wegovy through its platform and participating pharmacies. == Products and services == GoodRx started its telemedicine service GoodRx Care in September 2019. It lets people talk to a licensed provider online for common issues and get prescriptions even if they don't have insurance. They also run condition-specific subscription plans that bundle online doctor visits, FDA-approved meds, and home delivery into one monthly payment. On the weight management side, GoodRx offers prescriptions for GLP-1 drugs like semaglutide through their telemedicine platform. This got a boost when the oral version of Wegovy became widely available in the US in early 2026. GoodRx works with drug makers like Novo Nordisk to make some medications (including semaglutide options) more affordable for people paying cash. The telemedicine part took off after GoodRx bought HeyDoctor in 2019 and brought their virtual care tools into the main platform. == Key people == The Santa Monica-based startup was founded in September 2011 by Trevor Bezdek and former Facebook executives Doug Hirsch and Scott Marlette. Marlette was one of the first 20 employees at Facebook and built Facebook's photo application. In 2005, Hirsch was the Vice President of Product at Facebook, working closely with Mark Zuckerberg. Bezdek and Hirsch served as co-chief executive officers until April 2023, when they stepped down from those roles and technology executive Scott Wagner was appointed interim chief executive officer. Bezdek became chair of the board, while Hirsch took on the role of chief mission officer. In December 2024, GoodRx announced that healthcare executive Wendy Barnes would become president and chief executive officer effective January 1, 2025. As of 2025, Barnes serves as the company’s CEO, while Trevor Bezdek and Scott Wagner serve as co-chairs of the board, and Doug Hirsch remains involved as a co-founder and senior executive. == Controversy == On February 25, 2020, Consumer Reports published an article stating that GoodRx shared user data—specifically, pseudonymized advertising ID numbers that companies use to track the behavior of web users across websites, the names of the drugs that users browsed, and the pharmacies where users sought to fill prescriptions—with Google, Facebook, and around twenty other Internet-based companies. A few days later, GoodRx released a statement saying that it had made changes to prevent user search data on medical conditions and pharmaceuticals from being shared with Facebook. In March 2020, GoodRx stopped sending data about user prescriptions to Facebook. On February 1, 2023, the Federal Trade Commission fined GoodRx US$1.5 million for violations of the Breach Notification Rule and the Federal Trade Commission Act for allegedly failing to obtain specific, informed, and unambiguous consent from users before disclosing health-related information to Facebook and Google. In November 2024, independent pharmacies filed at least three class action lawsuits against GoodRx and major pharmacy benefit managers. The cases, brought by independent pharmacies in California, Michigan, Pennsylvania, and Rhode Island, allege that GoodRx and the PBMs collaborated to suppress reimbursements for generic prescription drugs. They allege that agreements using GoodRx’s software suppressed reimbursements for generic drugs and violated the Sherman Antitrust Act. The suits claim the practices amount to price fixing which harms small pharmacies while benefiting PBMs and their affiliates. GoodRx settled both the 2023 FTC action and the 2025 class action lawsuit without admitting wrongdoing.
NFA minimization
In automata theory (a branch of theoretical computer science), NFA minimization is the task of transforming a given nondeterministic finite automaton (NFA) into an equivalent NFA that has a minimum number of states, transitions, or both. While efficient algorithms exist for DFA minimization, NFA minimization is PSPACE-complete. No efficient (polynomial time) algorithms are known, and under the standard assumption that P ≠ PSPACE, none exist. The most efficient known algorithm is the Kameda–Weiner algorithm. == Non-uniqueness of minimal NFA == Unlike deterministic finite automata, minimal NFAs may not be unique. There may be multiple NFAs with the same number of states that accept the same regular language, but for which there is no equivalent NFA or DFA with fewer states.